Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Romidepsin

FDA-approved product (powder, intravenous), marketed as Istodax, Romidepsin.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Romidepsin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cutaneous T-cell lymphoma
  • Mature T-cell and NK-cell non-Hodgkin lymphoma
  • Neoplasm
  • T-cell non-Hodgkin lymphoma
  • Unspecified peripheral T-cell lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Histone deacetylase (hdac) inhibitors
FDA pharmacologic class
Histone Deacetylase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Romidepsin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-3.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-2.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-3.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Romidepsin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

    NCT00037817 · start 2002-05-17

    Registered record
    Registry ID
    NCT00037817
    Conditions
    Advanced Esophageal Cancers; Primary Small Cell Lung Cancers; Non-Small-Cell Lung Carcinoma; Pleural Mesotheliomas; Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
    Interventions
    Decitabine; Depsipeptide; Celecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-05-17
    Completion
    2009-11-09
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Esophageal Cancers; Primary Small Cell Lung Cancers; Non-Small-Cell Lung Carcinoma; Pleural Mesotheliomas +1 more
    InterventionDecitabine; Depsipeptide; Celecoxib
    PhasePhase 1
    Registry statusCompleted

  • FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma

    NCT00042822 · start 2002-05

    Registered record
    Registry ID
    NCT00042822
    Conditions
    Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
    Interventions
    romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-05
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
    Interventionromidepsin
    PhasePhase 2
    Registry statusCompleted

  • Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma

    NCT00007345 · start 2001-03-08

    Registered record
    Registry ID
    NCT00007345
    Conditions
    Cutaneous T Cell Lymphoma; Peripheral T Cell Lymphoma
    Interventions
    Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-03-08
    Completion
    2015-07-27
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous T Cell Lymphoma; Peripheral T Cell Lymphoma
    InterventionRomidepsin
    PhasePhase 2
    Registry statusCompleted

  • FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

    NCT00020202 · start 2000-06

    Registered record
    Registry ID
    NCT00020202
    Conditions
    Extensive Stage Small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Recurrent Small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer
    Interventions
    FR901228
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-06
    Completion
    2007-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive Stage Small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Recurrent Small Cell Lung Cancer +2 more
    InterventionFR901228
    PhasePhase 2
    Registry statusCompleted

  • Depsipeptide in Treating Patients With Solid Tumors

    NCT00019318 · start 1997-08

    Registered record
    Registry ID
    NCT00019318
    Conditions
    Lymphoma
    Interventions
    romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1997-08
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionromidepsin
    PhasePhase 1
    Registry statusCompleted